Search Results

Containing any of the words

Only of the type

A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy Drug Clinical Trial

A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study Drug Clinical Trial

A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes. Drug Clinical Trial

"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2" Drug Clinical Trial

A randomized, double-blind placebo-controlled trial to evaluate the safety and efficacy of a SARS-CoV-2 inactivated vaccine among healthcare workers in Saudi Arabia Drug Clinical Trial

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) Drug Clinical Trial

A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis Drug Clinical Trial

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis Drug Clinical Trial

SFDA Warns Against Herbal Product “Montalin Jamu” Due to Containing Active Medicinal Ingredients Warnings

Dr. Aljadhey inspects SFDA’s work during Hajj News